Geode Capital Management
KAPA

Geode Capital Management’s Kairos Pharma KAPA Stock Holding History

Geode Capital Management’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.3K Sell
78,924
-32,366
-29% -$16.8K ﹤0.01% 4326
2026
Q1 		$62.2K Buy
111,290
+38,457
+53% +$25.8K ﹤0.01% 4264
2025
Q4 		$51.7K Buy
72,833
+7,033
+11% +$6.58K ﹤0.01% 4227
2025
Q3 		$77K Buy
65,800
+43,996
+202% +$50.3K ﹤0.01% 4192
2025
Q2 		$15.5K Buy
21,804
+1,371
+7% +$998 ﹤0.01% 4393
2025
Q1 		$19.1K Buy
+20,433
New +$26.2K ﹤0.01% 4355

Other funds holding KAPA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Geode Capital Management's KAPA Position: Q2 2026 in Review

Geode Capital Management reduced its Kairos Pharma (KAPA) stake by 29% in Q2 2026, selling an estimated $16.8K and leaving 78,924 shares worth $30.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4326.

Geode Capital Management first reported a position in KAPA in Q1 2025 and has held it in 6 quarters since. The position peaked at $77K in Q3 2025. 9 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

  • Geode Capital Management held 78,924 shares of Kairos Pharma worth $30.3K as of Q2 2026.
  • Geode Capital Management sold 32,366 Kairos Pharma shares in Q2 2026, an estimated $16.8K.
  • Kairos Pharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4326 holding.
  • Geode Capital Management first reported a position in Kairos Pharma in Q1 2025 and has held it in 6 quarters since.
  • Geode Capital Management's Kairos Pharma position peaked at $77K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.